Athanor Capital’s Forte Biosciences FBRX Stock Holding History

Athanor Capital’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-257	Closed	-$311K	–	735
2020 Q3	$311K	Buy	+257	New	+$170K	0.01%	414

Other funds holding FBRX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Athanor Capital's FBRX Position: Q4 2020 in Review

Athanor Capital sold out of Forte Biosciences (FBRX) in Q4 2020, closing a stake of 257 shares — an estimated $311K sold.

Athanor Capital first reported a position in FBRX in Q3 2020 and held it in 1 quarter. The position peaked at $311K in Q3 2020. 49 funds tracked by Wall St. Rank hold FBRX as of Q4 2020.

Athanor Capital reported no remaining Forte Biosciences position as of Q4 2020 after selling out during the quarter.
Athanor Capital sold 257 Forte Biosciences shares in Q4 2020, an estimated $311K.
Athanor Capital first reported a position in Forte Biosciences in Q3 2020 and held it in 1 quarter.
Athanor Capital's Forte Biosciences position peaked at $311K in Q3 2020.
49 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2020.

Based on Athanor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.